Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SRA737, gemcitabine, cisplatin · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Standard-Dose Triplet Combination | EXPERIMENTAL | SRA737 will be administered orally on Days 2, 3, 9, and 10 of each 21-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Gemcitabine will be administered intravenously on Days 1 and 8 of each 21-day cycle. Cisplatin will be administered on Day 1 of each 21-day cycle. Subjects can continue taking the study treatment if they are safely receiving clinical benefit and able to follow the requirements of the study. |
| Low-Dose Gemcitabine Combination | EXPERIMENTAL | SRA737 will be administered orally on Days 2, 3, 9, 10, 16, and 17 of each 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle. Gemcitabine will be administered intravenously on Days 1, 8, and 15 of each 28-day cycle. Subjects can continue taking the study treatment if they are safely receiving clinical benefit and able to follow the requirements of the study. |
| Name | Type | Description |
|---|---|---|
| SRA737, gemcitabine, cisplatin | DRUG | - |
| SRA737, gemcitabine | DRUG | - |
Key Inclusion Criteria: 1. For Dose Escalation: subjects with locally advanced or metastatic, histologically or cytologically proven solid tumor, relapsed after or progressing despite conventional treatment 2. Life expectancy of at least 12 weeks 3. World Health Organization (WHO) performance statu...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
SRA737 is an investigational small molecule being studied for the treatment of advanced solid tumors and advanced solid tumors or non-Hodgkin's lymphoma (NHL). It is in Phase 1 clinical development and is not yet approved by regulatory authorities.
SRA737 is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker GSK. The drug is currently in Phase 1 clinical trials for advanced cancer indications.
SRA737 is in Phase 1 clinical development. It has completed two Phase 1 trials, and it remains an investigational drug, meaning it has not received regulatory approval and is still being evaluated for safety and efficacy.
SRA737 has been studied in two completed Phase 1 trials. The first, NCT02797964, evaluated SRA737 alone in subjects with advanced solid tumors or non-Hodgkin's lymphoma. The second, NCT02797977, tested SRA737 in combination with gemcitabine and cisplatin or gemcitabine alone in advanced cancer subjects.
SRA737 is a small molecule designed to target specific pathways involved in cancer cell growth. As an investigational oncology drug, it is being studied for its potential to treat advanced solid tumors and non-Hodgkin's lymphoma by interfering with cancer cell mechanisms.